Speaker illustration

Doctor Eli Roth

University of Cincinnati, Cincinnati (United States of America)

Assessment of absolute reductions in LDL-C associated with alirocumab therapy: results from across the Phase 3 ODYSSEY programme

Event: ESC CONGRESS 2017

Topic: Lipids (Epidemiology and Prevention)

Session: Lipids

Thumbnail

This platform is supported by

logo Novo Nordisk